These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 15781613

  • 1. Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis.
    Uhrbom L, Kastemar M, Johansson FK, Westermark B, Holland EC.
    Cancer Res; 2005 Mar 15; 65(6):2065-9. PubMed ID: 15781613
    [Abstract] [Full Text] [Related]

  • 2. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
    Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC.
    Cancer Res; 2002 Oct 01; 62(19):5551-8. PubMed ID: 12359767
    [Abstract] [Full Text] [Related]

  • 3. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA.
    Oncogene; 2004 Jan 15; 23(2):379-85. PubMed ID: 14724566
    [Abstract] [Full Text] [Related]

  • 4. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma.
    Tchougounova E, Kastemar M, Bråsäter D, Holland EC, Westermark B, Uhrbom L.
    Oncogene; 2007 Sep 20; 26(43):6289-96. PubMed ID: 17438529
    [Abstract] [Full Text] [Related]

  • 5. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
    D'Amico M, Wu K, Di Vizio D, Reutens AT, Stahl M, Fu M, Albanese C, Russell RG, Muller WJ, White M, Negassa A, Lee HW, DePinho RA, Pestell RG.
    Cancer Res; 2003 Jun 15; 63(12):3395-402. PubMed ID: 12810676
    [Abstract] [Full Text] [Related]

  • 6. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
    D'Amico M, Wu K, Fu M, Rao M, Albanese C, Russell RG, Lian H, Bregman D, White MA, Pestell RG.
    Cancer Res; 2004 Jun 15; 64(12):4122-30. PubMed ID: 15205322
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
    Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.
    Cancer Res; 2006 Aug 01; 66(15):7473-81. PubMed ID: 16885344
    [Abstract] [Full Text] [Related]

  • 13. INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.
    Lachat Y, Diserens AC, Nozaki M, Kobayashi H, Hamou MF, Godard S, De Tribolet N, Hegi ME.
    Oncogene; 2004 Sep 09; 23(41):6854-63. PubMed ID: 15273738
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. p16(INK4a) and p53 deficiency cooperate in tumorigenesis.
    Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA.
    Cancer Res; 2002 May 15; 62(10):2761-5. PubMed ID: 12019151
    [Abstract] [Full Text] [Related]

  • 19. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.
    Holland EC, Hively WP, DePinho RA, Varmus HE.
    Genes Dev; 1998 Dec 01; 12(23):3675-85. PubMed ID: 9851974
    [Abstract] [Full Text] [Related]

  • 20. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.
    Ji P, Zhou X, Liu Q, Fuller GN, Phillips LM, Zhang W.
    Oncotarget; 2016 Apr 26; 7(17):23521-9. PubMed ID: 26993778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.